Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 4 of 4 results for bumetanide

  1. Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]

    In development Reference number: GID-TA11662 Expected publication date:  25 February 2026

    Technology appraisal guidance
    In development

  2. Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]

    In development Reference number: GID-TA11651 Expected publication date:  04 June 2026

    Technology appraisal guidance
    In development

  3. Sotatercept for treating pulmonary arterial hypertension [ID6163]

    In development Reference number: GID-TA11103 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA902)

    Evidence-based recommendations on dapagliflozin (Forxiga) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.

    Technology appraisal guidance
    Published
    21 June 2023
    View recommendations

    Sections for TA902